Diffusion/perfusion MR imaging of the liver: Practice, challenges, and future

Magnetic Resonance in Medical Sciences

Volumn 11, Issue 3, 2012, Pages 151-161

  Kanematsu, Masayuki ^a   Goshima, Satoshi ^a   Watanabe, Haruo ^a   Kondo, Hiroshi ^a   Kawada, Hiroshi ^a   Noda, Yoshifumi ^a   Moriyama, Noriyuki ^b  

^a GIFU UNIVERSITY HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Diffusion; Liver; Magnetic resonance imaging; Prefusion

Indexed keywords

DIFFUSION WEIGHTED IMAGING; HUMAN; LIVER; LIVER DISEASE; MAGNETIC RESONANCE ANGIOGRAPHY; METHODOLOGY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; REVIEW;

DIFFUSION MAGNETIC RESONANCE IMAGING; HUMANS; LIVER; LIVER DISEASES; MAGNETIC RESONANCE ANGIOGRAPHY; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84867872401     PISSN: 13473182     EISSN: 18802206     Source Type: Journal    
DOI: 10.2463/mrms.11.151     Document Type: Review

References (49)

1. Le Bihan D, Breton E, Lallemand D, Grenier P, Cabanis E, Laval-Jeantet M. MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology 1986; 161:401-407.
2. Higano S, Yun X, Kumabe T, et al. Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade andprognosis. Radiology 2006; 241:839-846.
3. Kim YJ, Chang KH, Song IC, et al. Brain abscess and necrotic or cystic brain tumor: discrimination with signal intensity on diffusion-weighted MR imaging. AJR Am J Roentgenol 1998; 171:1487-1490.
4. Ebisu T, Tanaka C, Umeda M, et al. Hemorrhagic and nonhemorrhagic stroke: diagnosis with diffusion-weighted and T2-weighted echo-planar MR imaging. Radiology 1997; 203:823-828.
5. Sodickson DK. Tailored SMASH image reconstructions for robust in vivo parallel MR imaging. Magn Reson Med 2000; 44:243-251.
6. Taouli B, Sandberg A, Stemmer A, et al. Diffusion-weighted imaging of the liver: comparison of navigator triggered and breathhold acquisitions. J Magn Reson Imaging 2009; 30:561-568.
7. International Working Party. Terminology of nodular hepatocellular lesions. Hepatology 1995; 22:983-993.
8. International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009; 49:658-664.
9. Sano K, Ichikawa T, Motosugi U, et al. Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging. Radiology 2011; 261:834-844.
10. Hardie AD, Kizziah MK, Rissing MS. Can the patient with cirrhosis be imaged for hepatocellular carcinoma without gadolinium?: Comparison of combined T2-weighted, T2*-weighted, and diffusion-weighted MRI with gadolinium-enhanced MRI using liver explantation standard. J Comput Assist Tomogr 2011; 35:711-715.
11. Nasu K, Kuroki Y, Tsukamoto T, Nakajima H, Mori K, Minami M. Diffusion-weighted imaging of surgically resected hepatocellular carcinoma: imaging characteristics and relationship among signal intensity, apparent diffusion coefficient, and histopathologic grade. AJR Am J Roentgenol 2009; 193:438-444.
12. Nishie A, Tajima T, Asayama Y, et al. Diagnostic performance of apparent diffusion coefficient for predicting histological grade of hepatocellular carcinoma. Eur J Radiol 2011; 80:e29-e33.
13. Nakashima O, Kojiro M. Recurrence of hepatocellular carcinoma: multicentric occurrence or intrahepati metastasis? A viewpoint in terms of pathology. J Hepatobiliary Pancreat Surg 2001; 8:404-409.
14. Yu JS, Chung JJ, Kim JH, et al. Detection of small intrahepatic metastases of hepatocellular carcinomas using diffusion-weighted imaging: comparison with conventional dynamic MRI. Magn Reson Imaging 2011; 29:985-992.
15. Motosugi U, Ichikawa T, Sou H, et al. Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging. Radiology 2010; 256:151-158.
16. Goshima S, Kanematsu M, Kondo H, et al. Evaluating local hepatocellular carcinoma recurrence post-transcatheter arterial chemoembolization: is diffusion-weighted MRI reliable as an indicator? J Magn Reson Imaging 2008; 27:834-839.
17. Yoshioka H, Nakagawa K, Shindou H, et al. MR imaging of the liver before and after transcatheter hepatic chemo-embolization for hepatocellular carcinoma. Acta Radiol 1990; 31:63-67.
18. Goshima S, Kanematsu M, Kondo H, et al. Diffusion-weighted imaging of the liver: optimizing b value for the detection and characterization of benign and malignant hepatic lesions. J Magn Reson Imaging 2008; 28:691-697.
19. Hardie AD, Naik M, Hecht EM, et al. Diagnosis of liver metastases: value of diffusion-weighted MRI compared with gadolinium-enhanced MRI. Eur Radiol 2010; 20:1431-1441.
20. Nasu K, Kuroki Y, Nawano S, et al. Hepatic metastases: diffusion-weighted sensitivity-encoding versus SPIO-enhanced MR imaging. Radiology 2006; 239:122-130.
21. Shimada K, Isoda H, Hirokawa Y, Arizono S, Shibata T, Togashi K. Comparison of gadolinium-EOB-DTPA-enhanced and diffusion-weighted liver MRI for detection of small hepatic metastases. Eur Radiol 2010; 20:2690-2698.
22. Chung WS, Kim MJ, Chung YE, et al. Comparison of gadoxetic acid-enhanced dynamic imaging and diffusion-weighted imaging for the preoperative evaluation of colorectal liver metastases. J Magn Reson Imaging 2011; 34:345-353.
23. Le Bihan D, Breton E, Lallemand D, Aubin ML, Vignaud J, Laval-Jeantet M. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology 1988; 168:497-505.
24. Yamada I, Aung W, Himeno Y, Nakagawa T, Shibuya H. Diffusion coefficients in abdominal organs and hepatic lesions: evaluation with intravoxel incoherent motion echo-planar MR imaging. Radiology 1999; 210:617-623.
25. Ikeda K, Saitoh S, Suzuki Y, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998; 28:930-938.
26. Lee SS. Review article: indicators and predictors of response to anti-viral therapy in chronic hepatitis C. Aliment Pharmacol Ther 2003; 17:611-621.
27. Ito K, Mitchell DG, Hann HW, et al. Progressive viral-induced cirrhosis: serial MR imaging findings and clinical correlation. Radiology 1998; 207:729-735.
28. Kato H, Kanematsu M, Zhang X, et al. Computeraided diagnosis of hepatic fibrosis: preliminary evaluation of MRI texture analysis using the finite difference method and an artificial neural network. AJR Am J Roentgenol 2007; 189:117-122.
29. Annet L, Peeters F, Abarca-Quinones J, Leclercq I, Moulin P, Van Beers BE. Assessment of diffusion-weightedMR imaging in liver fibrosis. JMagn Reson Imaging 2007; 25:122-128.
30. Taouli B, Tolia AJ, Losada M, et al. Diffusionweighted MRI for quantification of liver fibrosis: preliminary experience. AJR Am J Roentgenol 2007; 189:799-806.
31. Luciani A, Vignaud A, Cavet M, et al. Liver cirrhosis: intravoxel incoherent motion MR imaging--pilot study. Radiology 2008; 249:891-899.
32. Atkinson DJ, Burstein D, Edelman RR. First-pass cardiac perfusion: evaluation with ultrafast MR imaging. Radiology 1990; 174:757-762.
33. Berthezeàne Y, Vexler V, Cleáment O, Muähler A, Moseley ME, Brasch RC. Contrast-enhanced MR imaging of the lung: assessments of ventilation and perfusion. Radiology 1992; 183:667-672.
34. Warach S, Levin JM, Schomer DL, Holman BL, Edelman RR. Hyperperfusion of ictal seizure focus demonstrated by MR perfusion imaging. AJNR Am J Neuroradiol 1994; 15:965-968.
35. Watkins S, McGeoch R, Lyne J, et al. Validation of magnetic resonance myocardial perfusion imaging with fractional flow reserve for the detection of significant coronary heart disease. Circulation 2009; 120:2207-2213.
36. Schaefer PW, Ozsunar Y, He J, et al. Assessing tissue viability with MR diffusion and perfusion imaging. AJNR Am J Neuroradiol 2003; 24:436-443.
37. Reimer P, Saini S, Kwong KK, Cohen MS, Weissleder R, Brady TJ. Dynamic gadolinium-enhanced echo-planar MR imaging of the liver: effect of pulse sequence and dose on enhancement. J Magn Reson Imaging 1994; 4:331-335.
38. Ichikawa T, Arbab AS, Araki T, et al. Perfusion MR imaging with a superparamagnetic iron oxide using T2-weighted and susceptibility-sensitive echoplanar sequences: evaluation of tumor vascularity in hepatocellular carcinoma. AJR Am J Roentgenol 1999; 173:207-213.
39. Annet L, Materne R, Danse E, Jamart J, Horsmans Y, Van Beers BE. Hepatic flow parameters measured with MR imaging and Doppler US: correlations with degree of cirrhosis and portal hypertension. Radiology 2003; 229:409-414.
40. Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol 1954; 30:969-977.
41. Sahani DV, Holalkere NS, Mueller PR, Zhu AX. Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue-initial experience. Radiology 2007; 243:736-743.
42. Hagiwara M, Rusinek H, Lee VS, et al. Advanced liver fibrosis: diagnosis with 3D whole-liver perfusion MR imaging--initial experience. Radiology 2008; 246:926-934.
43. Huppertz A, Balzer T, Blakeborough A, et al. European EOB Study Group. Improved detection of focal liver lesions atMR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology 2004; 230: 266-275.
44. Watanabe H, Kanematsu M, Goshima S, et al. Staging hepatic fibrosis: comparison of gadoxetate disodium-enhanced and diffusion-weighted MR imaging--preliminary observations. Radiology 2011; 259:142-150.
45. Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 2009; 69:223-240.
46. Schraml C, Schwenzer NF, Martirosian P, et al. Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results. AJR Am J Roentgenol 2009; 193:W301-W307.
47. Lewin M, Fartoux L, Vignaud A, ArriveáL, Menu Y, Rosmorduc O. The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study. Eur Radiol 2011; 21:281-290.
48. Wu EX, Cheung MM. MR diffusion kurtosis imaging for neural tissue characterization. NMR Biomed 2010; 23:836-848.
49. Schmitt B, Zamecnik P, ZaissM, et al. A new contrast in MR mammography by means of chemical exchange saturation transfer (CEST) imaging at 3 Tesla: preliminary results. Rofo 2011; 183:1030-1036.